Windtree Therapeutics (WINT) to Release Earnings on Friday

Windtree Therapeutics (NASDAQ:WINT) is set to release its earnings data on Friday, March 29th.

Windtree Therapeutics Stock Up 4.0 %

Shares of WINT stock opened at $0.37 on Thursday. The stock’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.74. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.40 and a current ratio of 2.40. Windtree Therapeutics has a twelve month low of $0.28 and a twelve month high of $18.48. The company has a market capitalization of $1.89 million, a price-to-earnings ratio of -0.02 and a beta of 0.60.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new position in Windtree Therapeutics in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Windtree Therapeutics in the 4th quarter worth approximately $28,000. Envestnet Asset Management Inc. increased its position in Windtree Therapeutics by 894.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after buying an additional 96,515 shares during the period. Millennium Management LLC increased its position in Windtree Therapeutics by 411.1% in the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after buying an additional 64,232 shares during the period. Finally, Vanguard Group Inc. bought a new position in Windtree Therapeutics in the 3rd quarter worth approximately $40,000. 29.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.